Telemonitoring Study - for Chronic Myeloid Leukemia (CML)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

NCT01011998

Chronic Myelogenous Leukemia

WITHDRAWN PHASE2

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

NCT00114959

Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic, Accelerated-Phase Blast Phase +1 more

TERMINATED PHASE2

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

NCT00038649

Myelogenous Leukemia, Chronic, Chronic Phase

TERMINATED PHASE2

Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

NCT00386373

Leukemia

COMPLETED NA

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00577694

Leukemia

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, controlled pilot study to introduce eMedonline telemonitoring technology to CML patients taking Gleevec or Tasigna. eMedonline will be used to automatically collect time-dose specific medication data for individual patients, including dosing times, missed doses, adverse events and e-diary data. All data will be available to research staff for remote review via Web interface. Adverse events and non-adherence will prompt interventions including supportive care counseling.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

eMedonline access

patients will have access to eMedonline access for 3 months

Group Type EXPERIMENTAL

eMedonline access

Intervention Type BEHAVIORAL

patients will be given access to eMedonline use for 3 months

no access to eMedonline

patients will be followed for 3 months with no access to eMedonline

Group Type OTHER

no access to eMedonline

Intervention Type BEHAVIORAL

patients will be followed for 3 months but will not use eMedonline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no access to eMedonline

patients will be followed for 3 months but will not use eMedonline

Intervention Type BEHAVIORAL

eMedonline access

patients will be given access to eMedonline use for 3 months

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Telemonitoring system e-diary electronic diary Telemonitoring system e-diary electronic diary

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18 years of age or older.
* Pathologically documented diagnosis of Chronic Phase CML (Ph+) in whom treating physician has determined that treatment with imatinib or nilotinib is appropriate
* Patients currently receiving Gleevec (imatinib) 300-600 mg daily or Tasigna (nilotinib) 300-400 mg twice daily
* ECOG Performance status 0, 1, or 2
* Adequate end organ function, defined as:

* Total bilirubin \< 1.5 xULN
* SGOT and SGPT \<2.5 x ULN
* Creatinine \< 1.5 x ULN
* ANC \> 1.5
* Platelets \> 100,000
* Female patients of child bearing potential must have a negative urine or serum pregnancy test at screening.
* Patient is able to read and speak English
* Patient is willing and able to use a cell phone
* Written, voluntary informed consent